| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 5.2 | 3.7 |
| Profit before tax | -60.5 | -71.9 |
| Net income | -61.2 | -80.5 |
| EPS (diluted, $ a share) | $-0.88 | $-1.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +40.4% |
|---|
10-Q filed with the SEC, NASDAQ: QURE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
uniQure N.V.: key numbers
- Share price
- $21.88Close, Nov 16
- Market cap
- $1.53B
- Shares outstanding
- 70.14MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from uniQure N.V.
All →uniQure Insider David D. Meek Sells $193K of Stock
David D. Meek sold 9,080 shares of uniQure N.V. at $21.25 a share, worth $193K in total on Nov 6, 2026. Shares held after the trade: 30,667 (-22.8%).
- Value
- $193K
- Shares
- 9,080
- Price
- $21.25
- Holding change
- -22.8%
- Trade date
- Nov 6, 2026
uniQure Earnings Call: Key Takeaways
uniQure is transitioning to a commercial-stage entity with FDA priority review for AMT-130, backed by a strong $768.4 million cash position and significant slowing of Huntington's disease progression.
- Call
- Nov 4, 2026, 8:30 AM ET
uniQure Financial Results
uniQure reported Q3 2026 financial results, highlighting a cash position of $768.4 million which is expected to fund operations into 2030. The company also announced that the FDA has granted Priority Review for its BLA for AMT-130 in Huntington’s disease with a PDUFA date of May 1, 2027.
“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease. We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”
Matthew Kapusta, chief executive officer at uniQure
“As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans.”
Matthew Kapusta, chief executive officer at uniQure
uniQure Business Update
uniQure announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington’s disease, for review under the Accelerated Approval pathway. The FDA granted the application Priority Review with a PDUFA target action date of May 1, 2027, and is tentatively planning an Advisory Committee meeting to discuss the application.
- Counterparty
- FDA
uniQure Clinical Trial Data
uniQure N.V. released a clinical program update for AMT-130 (ifezuntirgene inilparvovec), its gene therapy candidate for Huntington’s disease. The update includes long-term data from ongoing Phase I/II clinical trials and details regarding the enrollment of a fourth cohort. The company is also evaluating neurofilament light chain (NfL) in cerebrospinal fluid as a potential biomarker for disease severity.